Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06185972

Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer

Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Sunnybrook Health Sciences Centre · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to demonstrate the efficacy and response of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.

Detailed description

The approach uses relatively low-power ultrasound, operating with lower power levels than high intensity focused ultrasound and ultrasound-based hyperthermia techniques, delivered on the Sonalleve platform. The tumour will be sonicated before the radiation to enhance the effect of therapy. The technique is spatially targeted and stimulates microbubbles using low-power ultrasonic fields in the tumour location only. The primary aim is to evaluate tumour response to MRg-FUS + MB and radiation, as measured radiologically or clinically within the treated therapeutic target regions.The secondary aim of this research is to evaluate early and late effect profiles of MRI- guided ultrasound stimulated microbubble treatment and radiation in patients with inoperable breast/chest wall tumours or LABC at 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months and 1 year after treatment.

Conditions

Interventions

TypeNameDescription
DRUGDefinityStimulation of Definity microbubbles using Sonalleve device within tumour vasculature
DEVICESonalleve Focused Ultrasound DeviceSonalleve Focused Ultrasound Device

Timeline

Start date
2024-07-25
Primary completion
2026-02-01
Completion
2029-02-01
First posted
2023-12-29
Last updated
2024-09-27

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06185972. Inclusion in this directory is not an endorsement.